Penn Virginia Corp (PVA) 16.72 $PVA
pSivida Presents Preclinical Data Demonstrating Sustained Release of Avastin Using Tethadur at ARVO Annual Meeting
Business Wire - Mon May 05, 2:00PM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that the Company presented the first peer-reviewed preclinical data demonstrating the use of pSivida's Tethadur(TM) technology to provide sustained release of Avastin at the 14th Annual Meeting of ARVO (Association for Research in Vision and Ophthalmology).
pSivida Corp Announces Third Quarter 2014 Financial Results Release Date and Conference Call Information
Business Wire - Fri May 02, 7:01AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2014 will be released after the market close on Tuesday, May 13, 2014, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET.
Penn Virginia Corporation Schedules Conference Call for First Quarter 2014 Results
GlobeNewswire - Mon Apr 28, 7:25AM CDT
Penn Virginia Corporation (NYSE VA) today announced that it will release its first quarter 2014 results after the market closes on Monday, May 12, 2014 and hold a conference call / webcast on Tuesday, May 13, 2014 at 10:00 a.m. ET.
pSivida Reports Australia/New Zealand Distribution Agreement for ILUVIEN(R) for DME
Business Wire - Mon Apr 28, 6:06AM CDT
pSivida Corp. (NASDAQ SDV) (ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has signed an exclusive agreement with Specialised Therapeutics Australia (STA) for the distribution in Australia and New Zealand of ILUVIEN(R) for the treatment of diabetic macular edema (DME). Under the agreement, STA also will handle all regulatory and commercial activities for ILUVIEN in those countries.
Penn Virginia Up 8.5% Since SmarTrend Uptrend Call (PVA)
Comtex SmarTrend(R) - Fri Apr 25, 9:28AM CDT
SmarTrend identified an Uptrend for Penn Virginia (NYSE VA) on March 19th, 2014 at $15.92. In approximately 1 month, Penn Virginia has returned 8.45% as of today's recent price of $17.26.
Stock Price Updates and Schedules of Earnings Releases & Conferences Calls - Analyst Notes on Penn Virginia, Sanchez Energy, Matador Resources, Stone Energy and Swift Energy
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Penn Virginia Corporation (NYSE: PVA), Sanchez Energy Corporation (NYSE: SN), Matador Resources Company (NYSE: MTDR), Stone Energy Corp. (NYSE: SGY) and Swift Energy Co. (NYSE: SFY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1540-100free.
pSivida Selected to Present at 2014 Opthalmology Innovation Summit
Business Wire - Wed Apr 23, 7:45AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The Ophthalmology Innovation Summit (OIS), April 24, 2014 at the Seaport Hotel in Boston, MA. pSivida's president and chief executive officer, Dr. Paul Ashton, will discuss sustained delivery of antibodies and other large biologics with pSivida's Tethadur(TM) technology.
NYSE stocks posting largest percentage increases
AP - Wed Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
The Shorts Will Get Crushed on Swift Energy Company
Matt DiLallo, The Motley Fool - Motley Fool - Mon Apr 14, 10:35AM CDT
Swift Energy short sellers could get pulverized. Photo credit: Flickr/ Gavin Shire-USFWS . It has been a rough start to the year for long-term investors of Swift Energy . The stock is down 22% so far in 2014. Some investors believe it's not...
pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN(R)
Business Wire - Mon Apr 14, 6:04AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 for ILUVIEN(R) following the recent resubmission of the New Drug Application (NDA) by pSivida's licensee, Alimera Sciences. The FDA acknowledged the resubmission as received as a complete class 2 response to the FDA's October 2013 complete response letter.
This Texas Oil Play Keeps Getting Bigger
Matt DiLallo, The Motley Fool - Motley Fool - Fri Apr 11, 8:50AM CDT
Photo credit: ConocoPhillips The Eagle Ford Shale just keeps getting bigger. ConocoPhillips was the latest company to point out that its oil position in the play is much bigger than previously thought. In fact, the company now estimates...
Is It Too Late for Investors to Follow George Soros Into Penn Virginia Corporation?
Rupert Hargreaves, The Motley Fool - Motley Fool - Wed Apr 09, 1:12PM CDT
Legendary investor George Soros, known as the man who broke the Bank of England, recently revealed that his investment vehicle had acquired a near 10% stake in Penn Virginia Corporation . Soros has built his reputation as a value investor, and...
Global Coal Bed Methane (CBM) Market 2014-2018 with Arrow Energy, BG Group, BP, Chevron, Dart Energy, ExxonMobil & Royal Dutch Shell Dominating
M2 - Fri Apr 04, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jb435t/global_coal_bed) has announced the addition of the "Global Coal Bed Methane (CBM) Market 2014-2018 with Arrow Energy, BG Group, BP, Chevron, Dart Energy, ExxonMobil & Royal Dutch Shell Dominating" report to their offering. One of the major drivers in this market is the shifting focus from conventional gas sources due to the depletion of fossil fuels. Governments across the globe are being forced to shift their focus to alternative sources of gas supply including CBM, which is propelling the growth of the Global CBM market. Over the years, there has been a tremendous increase in technological advancements in the Global CBM market, which has resulted in the higher extraction of CBM from major reservoirs across the world. These technological advancements include the CBM production mechanism, the development of techniques for accurate isothermic testing and determination of gas levels, the development of well log interpretation, and well simulation models. Also, huge investments are being made in R&D to improve the efficient recovery of CBM through horizontal drilling while reducing the lead time and cost. The overall volume of production as well as the cost and risk have significantly declined due to these rapid technological advancements in the industry. Therefore, it is expected that technological advancements will be one of the key trends propelling the growth of the Global CBM market during the forecast period. Further, the report states that one of the major challenges confronting the market is the long dewatering period for CBM. The dewatering of a CBM well takes a lot of time and increases the overall cost of development of CBM wells. Key vendors dominating this space are: - Arrow Energy Pty Ltd - BG Group plc - BP plc - Chevron Corp. - Dart Energy Ltd. - ExxonMobil Corp. - Royal Dutch Shell plc. Other vendors mentioned in the report are: - Aberdeen Drilling Management Ltd. - Alkane Energy - BHP Billiton - Cathy Oil and Gas Ltd - CBM Asia Development Corp - China United Coalbed Methane Corp - Constellation Energy Group - ConocoPhillips Co - Devon Energy Corp. - Double Eagle Petroleum Co. - Encana Corp - Essar Energy Plc - Gazprom - GDF Suez S.A - Green Dragon Gas - Penn Virginia Corp. - Osaka Gas Co. Ltd. - Sinopec - Storm Cat Energy Corp. - Strait Oil & Gas Ltd - Tlou Energy - Total S.A. - Warren Resources Inc. Key questions answered in this report: - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/jb...l_coal_bed
pSivida CEO to Discuss Company's Sustained Release Delivery System for Biologics at Two Upcoming Conferences
Business Wire - Tue Apr 01, 9:09AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida's president and chief executive officer, Dr. Paul Ashton, will discuss pSivida's Tethadur(TM) technology designed to provide sustained delivery of biologics at The World Ophthalmology Conference in Tokyo, April 2-6 and at the SMi Inaugural Conference on Biosimilars and Biobetters USA, in Iselin, New Jersey, April 7-8.
What Does Soros See in This Company That Others Don't?
Callum Turcan, The Motley Fool - Motley Fool - Fri Mar 28, 12:40PM CDT
What does George Soros see in Penn Virginia Corp ? this company hasn't posted a profit in the past five years! That hasn't stopped Soros from buying up 9.2% of Penn Virginia's shares though. Should you follow suit or has Soros made the wrong call? ...
Your Need-to-Know Energy News
Taylor Muckerman and Joel South, The Motley Fool - Motley Fool - Thu Mar 27, 7:00AM CDT
The following video encapsulates some of the most notable news stories from March 25, 2014. Our energy analysts, Joel South and Taylor Muckerman discuss everything from ExxonMobil's troubles after an oil spill in the Gulf of Mexico to a the United...
pSivida Announces Resubmission of New Drug Application for ILUVIEN(R)
Business Wire - Thu Mar 27, 6:05AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). In the resubmission, pSivida's licensee, Alimera Sciences, responded to questions raised in the FDA's October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe.
Selling a Business Isn't as Easy as it Once Was
Taylor Muckerman and Joel South, The Motley Fool - Motley Fool - Wed Mar 26, 9:27AM CDT
Floyd Wilson isn't one to shy away from publicly commenting on his company's operations. Not too long ago, he was filling investors in on how poorly Halcon Resources' Utica wells were performing. Now, he has officially put the company he founded...
3 Things Swift Energy Company Needs to do to Win Back Investors
Matt DiLallo, The Motley Fool - Motley Fool - Tue Mar 25, 10:00AM CDT
Swift Energy 's stock has cratered since the start of the year, dropping nearly 23% even as the broader market is roughly flat. A rough first quarter that saw the Houston-based company's oil wells underperform expectations is the main cause of the...
Can George Soros Get a Fair Deal for Penn Virginia Corp.?
Joel South and Taylor Muckerman, The Motley Fool - Motley Fool - Fri Mar 21, 12:00PM CDT
After George Soros increased his ownership stake in Penn Virginia to 9.2%, in addition to taking an active role in the oil and natural gas producer, shares soared higher. Soros expressed interested in exploring strategic alternatives for Penn...
pSivida Presents Preclinical Data Demonstrating Sustained Release of Avastin Using Tethadur at ARVO Annual Meeting
Business Wire - Mon May 05, 2:00PM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that the Company presented the first peer-reviewed preclinical data demonstrating the use of pSivida's Tethadur(TM) technology to provide sustained release of Avastin at the 14th Annual Meeting of ARVO (Association for Research in Vision and Ophthalmology).
pSivida Corp Announces Third Quarter 2014 Financial Results Release Date and Conference Call Information
Business Wire - Fri May 02, 7:01AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its financial results for the third quarter of fiscal year 2014 will be released after the market close on Tuesday, May 13, 2014, followed the same day by a conference call and live webcast scheduled for 4:30 p.m. ET. Penn Virginia Corporation Schedules Conference Call for First Quarter 2014 Results
GlobeNewswire - Mon Apr 28, 7:25AM CDT
Penn Virginia Corporation (NYSE
VA) today announced that it will release its first quarter 2014 results after the market closes on Monday, May 12, 2014 and hold a conference call / webcast on Tuesday, May 13, 2014 at 10:00 a.m. ET. pSivida Reports Australia/New Zealand Distribution Agreement for ILUVIEN(R) for DME
Business Wire - Mon Apr 28, 6:06AM CDT
pSivida Corp. (NASDAQ
SDV) (ASX VA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has signed an exclusive agreement with Specialised Therapeutics Australia (STA) for the distribution in Australia and New Zealand of ILUVIEN(R) for the treatment of diabetic macular edema (DME). Under the agreement, STA also will handle all regulatory and commercial activities for ILUVIEN in those countries. Penn Virginia Up 8.5% Since SmarTrend Uptrend Call (PVA)
Comtex SmarTrend(R) - Fri Apr 25, 9:28AM CDT
SmarTrend identified an Uptrend for Penn Virginia (NYSE
VA) on March 19th, 2014 at $15.92. In approximately 1 month, Penn Virginia has returned 8.45% as of today's recent price of $17.26. Stock Price Updates and Schedules of Earnings Releases & Conferences Calls - Analyst Notes on Penn Virginia, Sanchez Energy, Matador Resources, Stone Energy and Swift Energy
PR Newswire - Thu Apr 24, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Penn Virginia Corporation (NYSE: PVA), Sanchez Energy Corporation (NYSE: SN), Matador Resources Company (NYSE: MTDR), Stone Energy Corp. (NYSE: SGY) and Swift Energy Co. (NYSE: SFY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1540-100free.
pSivida Selected to Present at 2014 Opthalmology Innovation Summit
Business Wire - Wed Apr 23, 7:45AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida has been selected for the Ophthalmic Companies Showcase at The Ophthalmology Innovation Summit (OIS), April 24, 2014 at the Seaport Hotel in Boston, MA. pSivida's president and chief executive officer, Dr. Paul Ashton, will discuss sustained delivery of antibodies and other large biologics with pSivida's Tethadur(TM) technology.
NYSE stocks posting largest percentage increases
AP - Wed Apr 16, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
The Shorts Will Get Crushed on Swift Energy Company
Matt DiLallo, The Motley Fool - Motley Fool - Mon Apr 14, 10:35AM CDT
Swift Energy short sellers could get pulverized. Photo credit: Flickr/ Gavin Shire-USFWS . It has been a rough start to the year for long-term investors of Swift Energy . The stock is down 22% so far in 2014. Some investors believe it's not...
pSivida Announces September 26, 2014 PDUFA Date for ILUVIEN(R)
Business Wire - Mon Apr 14, 6:04AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) goal date of September 26, 2014 for ILUVIEN(R) following the recent resubmission of the New Drug Application (NDA) by pSivida's licensee, Alimera Sciences. The FDA acknowledged the resubmission as received as a complete class 2 response to the FDA's October 2013 complete response letter.
This Texas Oil Play Keeps Getting Bigger
Matt DiLallo, The Motley Fool - Motley Fool - Fri Apr 11, 8:50AM CDT
Photo credit: ConocoPhillips The Eagle Ford Shale just keeps getting bigger. ConocoPhillips was the latest company to point out that its oil position in the play is much bigger than previously thought. In fact, the company now estimates...
Is It Too Late for Investors to Follow George Soros Into Penn Virginia Corporation?
Rupert Hargreaves, The Motley Fool - Motley Fool - Wed Apr 09, 1:12PM CDT
Legendary investor George Soros, known as the man who broke the Bank of England, recently revealed that his investment vehicle had acquired a near 10% stake in Penn Virginia Corporation . Soros has built his reputation as a value investor, and...
Global Coal Bed Methane (CBM) Market 2014-2018 with Arrow Energy, BG Group, BP, Chevron, Dart Energy, ExxonMobil & Royal Dutch Shell Dominating
M2 - Fri Apr 04, 8:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/jb435t/global_coal_bed) has announced the addition of the "Global Coal Bed Methane (CBM) Market 2014-2018 with Arrow Energy, BG Group, BP, Chevron, Dart Energy, ExxonMobil & Royal Dutch Shell Dominating" report to their offering. One of the major drivers in this market is the shifting focus from conventional gas sources due to the depletion of fossil fuels. Governments across the globe are being forced to shift their focus to alternative sources of gas supply including CBM, which is propelling the growth of the Global CBM market. Over the years, there has been a tremendous increase in technological advancements in the Global CBM market, which has resulted in the higher extraction of CBM from major reservoirs across the world. These technological advancements include the CBM production mechanism, the development of techniques for accurate isothermic testing and determination of gas levels, the development of well log interpretation, and well simulation models. Also, huge investments are being made in R&D to improve the efficient recovery of CBM through horizontal drilling while reducing the lead time and cost. The overall volume of production as well as the cost and risk have significantly declined due to these rapid technological advancements in the industry. Therefore, it is expected that technological advancements will be one of the key trends propelling the growth of the Global CBM market during the forecast period. Further, the report states that one of the major challenges confronting the market is the long dewatering period for CBM. The dewatering of a CBM well takes a lot of time and increases the overall cost of development of CBM wells. Key vendors dominating this space are: - Arrow Energy Pty Ltd - BG Group plc - BP plc - Chevron Corp. - Dart Energy Ltd. - ExxonMobil Corp. - Royal Dutch Shell plc. Other vendors mentioned in the report are: - Aberdeen Drilling Management Ltd. - Alkane Energy - BHP Billiton - Cathy Oil and Gas Ltd - CBM Asia Development Corp - China United Coalbed Methane Corp - Constellation Energy Group - ConocoPhillips Co - Devon Energy Corp. - Double Eagle Petroleum Co. - Encana Corp - Essar Energy Plc - Gazprom - GDF Suez S.A - Green Dragon Gas - Penn Virginia Corp. - Osaka Gas Co. Ltd. - Sinopec - Storm Cat Energy Corp. - Strait Oil & Gas Ltd - Tlou Energy - Total S.A. - Warren Resources Inc. Key questions answered in this report: - What will the market size be in 2018 and what will the growth rate be? - What are the key market trends? - What is driving this market? - What are the challenges to market growth? - Who are the key vendors in this market space? - What are the market opportunities and threats faced by the key vendors? - What are the strengths and weaknesses of the key vendors? For more information visit http://www.researchandmarkets.com/research/jb...l_coal_bed
pSivida CEO to Discuss Company's Sustained Release Delivery System for Biologics at Two Upcoming Conferences
Business Wire - Tue Apr 01, 9:09AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release products for treating eye diseases, today announced that pSivida's president and chief executive officer, Dr. Paul Ashton, will discuss pSivida's Tethadur(TM) technology designed to provide sustained delivery of biologics at The World Ophthalmology Conference in Tokyo, April 2-6 and at the SMi Inaugural Conference on Biosimilars and Biobetters USA, in Iselin, New Jersey, April 7-8.
What Does Soros See in This Company That Others Don't?
Callum Turcan, The Motley Fool - Motley Fool - Fri Mar 28, 12:40PM CDT
What does George Soros see in Penn Virginia Corp ? this company hasn't posted a profit in the past five years! That hasn't stopped Soros from buying up 9.2% of Penn Virginia's shares though. Should you follow suit or has Soros made the wrong call? ...
Your Need-to-Know Energy News
Taylor Muckerman and Joel South, The Motley Fool - Motley Fool - Thu Mar 27, 7:00AM CDT
The following video encapsulates some of the most notable news stories from March 25, 2014. Our energy analysts, Joel South and Taylor Muckerman discuss everything from ExxonMobil's troubles after an oil spill in the Gulf of Mexico to a the United...
pSivida Announces Resubmission of New Drug Application for ILUVIEN(R)
Business Wire - Thu Mar 27, 6:05AM CDT
pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA). In the resubmission, pSivida's licensee, Alimera Sciences, responded to questions raised in the FDA's October 2013 complete response letter and provided a safety update, which included commercial experience with ILUVIEN in Europe.
Selling a Business Isn't as Easy as it Once Was
Taylor Muckerman and Joel South, The Motley Fool - Motley Fool - Wed Mar 26, 9:27AM CDT
Floyd Wilson isn't one to shy away from publicly commenting on his company's operations. Not too long ago, he was filling investors in on how poorly Halcon Resources' Utica wells were performing. Now, he has officially put the company he founded...
3 Things Swift Energy Company Needs to do to Win Back Investors
Matt DiLallo, The Motley Fool - Motley Fool - Tue Mar 25, 10:00AM CDT
Swift Energy 's stock has cratered since the start of the year, dropping nearly 23% even as the broader market is roughly flat. A rough first quarter that saw the Houston-based company's oil wells underperform expectations is the main cause of the...
Can George Soros Get a Fair Deal for Penn Virginia Corp.?
Joel South and Taylor Muckerman, The Motley Fool - Motley Fool - Fri Mar 21, 12:00PM CDT
After George Soros increased his ownership stake in Penn Virginia to 9.2%, in addition to taking an active role in the oil and natural gas producer, shares soared higher. Soros expressed interested in exploring strategic alternatives for Penn...
